18F-FDG PET/CT in staging and metabolic activity assessment of multiple myeloma

作者：Lijuan Di, Jianhua Zhang, Rongfu Wang, Zhanli Fu, Yan Fan, Xuchu Zhang, Guangyu Zhao, Yonggang Cui, Meng Liu, Lei Kang, Xuhe Liao · 发表于：Zhonghua heyixue yu fenzi yingxiang zazhi · 年份：2017 · DOI：10.3760/cma.j.issn.2095-2848.2017.01.009 · 研究领域：Hematological disorders and diagnostics、Bone and Joint Diseases、Lung Cancer Treatments and Mutations

Objective To investigate the clinical value of 18F-FDG PET/CT in staging multiple myeloma (MM) and evaluating the glucose metabolic activity of MM. Methods A total of 25 MM patients (13 males, 12 females, age: 39-67 years) from May 2010 to April 2015 were enrolled in this retrospective study. The SUVmax of each patient was recorded. D-S plus staging according to 18F-FDG PET/CT was compared with the traditional D-S staging. The SUVmax and the percentage of plasmacytes of bone marrow of phase Ⅲ and non-phase Ⅲ (phaseⅠand Ⅱ) according to D-S plus staging were compared. Two-sample t test and Wilcoxon rank sum test were used to analyze the data. Results In 25 MM patients, the range of SUVmax of lesions was 1.8-12.0 and the mean value was 5.15±2.74. According to D-S staging, the numbers of patients with phase Ⅰ, Ⅱ and Ⅲ were 7, 4 and 14, respectively. While the numbers were 3, 1 and 21 by D-S plus staging. Based on the D-S plus staging system, stages of 7 patients (28%, 7/25) were changed. According to the D-S plus staging system, the SUVmax between phase Ⅲ and non-phase Ⅲ patients was significantly different (5.75±2.54 vs 3.00±0.70; t=2.12, P 0.05). Conclusion 18F-FDG PET/CT is of clinical importance for MM staging and metabolic activity assessment of MM. Key words: Multiple myeloma; Neoplasm staging; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose